Smith & Nephew (NYSE: SNN) reported earnings on May 3. Here are the numbers you need to know.

The 10-second takeaway
For the quarter ended March 31 (Q1), Smith & Nephew met expectations on revenues and missed estimates on earnings per share.

Compared with the prior-year quarter, revenue grew slightly and GAAP earnings per share increased.

Gross margins increased, operating margins were steady, net margins grew.

Revenue details
Smith & Nephew reported revenue of $1.08 billion. The 10 analysts polled by S&P Capital IQ foresaw revenue of $1.08 billion on the same basis. GAAP reported sales were 2.3% higher than the prior-year quarter's $1.06 billion.

My

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
EPS came in at $0.18. The four earnings estimates compiled by S&P Capital IQ averaged $0.96 per share. GAAP EPS of $0.18 for Q1 were 5.9% higher than the prior-year quarter's $0.17 per share.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
For the quarter, gross margin was 74.9%, 110 basis points better than the prior-year quarter. Operating margin was 21.9%, about the same as the prior-year quarter. Net margin was 14.9%, 10 basis points better than the prior-year quarter.

Looking ahead
Next quarter's average estimate for revenue is $1.08 billion. On the bottom line, the average EPS estimate is $0.93.

Next year's average estimate for revenue is $4.31 billion. The average EPS estimate is $3.31.

Investor sentiment
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 117 members out of 127 rating the stock outperform, and 10 members rating it underperform. Among 37 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 33 give Smith & Nephew a green thumbs-up, and four give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Smith & Nephew is hold, with an average price target of $51.60.

The health-care investing landscape is littered with also-rans and a few major winners. Is Smith & Nephew performing well enough for you? Read "Discover the Next Rule-Breaking Multibagger" to learn about a company David Gardner believes will deliver amazing returns during the next few years. Get instant access to this free report.